AMGN - Amgen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
197.39
+3.54 (+1.83%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close193.85
Open195.62
Bid193.91 x 800
Ask200.00 x 800
Day's Range194.15 - 198.09
52 Week Range163.31 - 210.19
Volume2,242,464
Avg. Volume2,509,146
Market Cap127.765B
Beta (3Y Monthly)1.53
PE Ratio (TTM)59.13
EPS (TTM)3.34
Earnings DateOct 30, 2018
Forward Dividend & Yield5.28 (2.67%)
Ex-Dividend Date2018-08-16
1y Target Est205.15
Trade prices are not sourced from all markets
  • AbbVie Settles With Novartis to Delay Humira Biosimilar in US
    Zacks3 days ago

    AbbVie Settles With Novartis to Delay Humira Biosimilar in US

    AbbVie (ABBV) strikes a deal with Sandoz, the generic arm of Novartis, to launch its biosimilar Humira in the United States on Sep 30, 2023.

  • Reuters4 days ago

    Abbvie settles Humira patent disputes with Novartis unit

    Abbvie Inc said on Thursday it settled all patent disputes with Novartis AG, granting it a non-exclusive license to manufacture and sell a copycat version of blockbuster drug, Humira. Abbvie, however, did not disclose details regarding the royalties it will receive from Novartis generics unit, Sandoz, as part of the agreement. Shares of Abbvie rose 2.39 percent to $92.87 in after-market trading.

  • Here's Why Coherus BioSciences Fell 18.1% in September
    Motley Fool4 days ago

    Here's Why Coherus BioSciences Fell 18.1% in September

    Enthusiasm for the biopharma is wearing off despite its announcement of an important commercial milestone.

  • Here's Why bluebird bio Dropped 13.3% in September
    Motley Fool4 days ago

    Here's Why bluebird bio Dropped 13.3% in September

    The biopharma's multimonth stock slide continued, courtesy of promising preclinical results released by Amgen.

  • Healthcare Stocks in the Red amid Broader Market Sell-Off
    Market Realist4 days ago

    Healthcare Stocks in the Red amid Broader Market Sell-Off

    Yesterday, most healthcare stocks were trading below their previous day’s closing price. Biotech players seem to have been hit the worst. However, all other sectors including pharmaceuticals, medical devices, and hospitals saw significant weakness. Johnson & Johnson (JNJ), Boston Scientific (BSX), Pfizer (PFE), Merck (MRK), and Bristol-Myers Squibb fell 1.1%, 2.1%, 2.6%, and 3.9%, respectively, yesterday. Major biotechnology players Gilead Sciences (GILD), Amgen (AMGN), Biogen (BIIB), and Novo Nordisk (NVO) fell 2.30%, 2.33%, 2.04%, and 1.81%, respectively.

  • Celgene: Multiple Myeloma Franchise Could Drive Growth
    Market Realist5 days ago

    Celgene: Multiple Myeloma Franchise Could Drive Growth

    How's Celgene Positioned before Its Third-Quarter Earnings? Celgene’s (CELG) hematology and oncology franchise consists of Revlimid, Pomalyst, Abraxane, Idhifa, Vidaza, Istodax, and Thalomid. Revlimid’s revenues grew from $3.9 billion in the first half of 2017 to $4.7 billion in the first half of 2018, which reflects ~19.6% growth YoY (year-over-year).

  • Tilary Buys Alef Biotechnology to Build Base in Latin America
    Zacks5 days ago

    Tilary Buys Alef Biotechnology to Build Base in Latin America

    Tilary (TLRY) acquires import and distribution partner, Alef Biotechnology to strengthen its base in Latin America.

  • Celgene: Analysts’ Views before Its Third-Quarter Earnings
    Market Realist5 days ago

    Celgene: Analysts’ Views before Its Third-Quarter Earnings

    Wall Street analysts expect Celgene to report a net income and EPS of $1.2 billion and $1.71, respectively, in the third quarter.

  • FDA Sets Action Date for Recro's Pain Management Candidate
    Zacks6 days ago

    FDA Sets Action Date for Recro's Pain Management Candidate

    The FDA has set an action date of Mar 24, 2019 for Recro's lead product candidate, intravenous (IV) meloxicam, for the management of moderate to severe pain.

  • 10 S&P 500 Stocks to Buy for the Long Term
    InvestorPlace6 days ago

    10 S&P 500 Stocks to Buy for the Long Term

    The last few days have been tough ones for too many investors in S&P 500 stocks. Though far from devastating, the existing backdrop of anxiety exacerbated the fear incited by the modest selloff. And traders still aren’t sure what the foreseeable future holds. In simplest terms, it’s just plain stressful.

  • Bausch's Bryhali Gets Tentative FDA Nod for Plaque Psoriasis
    Zacks6 days ago

    Bausch's Bryhali Gets Tentative FDA Nod for Plaque Psoriasis

    Bausch receives tentative FDA approval for the NDA for Bryhali (halobetasol propionate) Lotion, 0.01%, for the topical treatment of plaque psoriasis in adult patients.

  • Analysts Are Mostly Positive on Neurocrine Biosciences
    Market Realist6 days ago

    Analysts Are Mostly Positive on Neurocrine Biosciences

    Neurocrine Biosciences (NBIX) develops and commercializes therapies for neurology and endocrine disorders. Neurocrine Biosciences’ Ingrezza became the first FDA-approved drug to be approved for the treatment of individuals with tardive dyskinesia. Neurocrine Biosciences’ Ingrezza competes with Teva Pharmaceutical’s (TEVA) Austedo in the tardive dyskinesia drugs market.

  • Is Arrowhead Pharmaceuticals, Inc. a Buy on the Dip?
    Motley Fool7 days ago

    Is Arrowhead Pharmaceuticals, Inc. a Buy on the Dip?

    A market beatdown following some good news has investors scratching their heads.

  • See what the IHS Markit Score report has to say about Amgen Inc.
    Markit7 days ago

    See what the IHS Markit Score report has to say about Amgen Inc.

    Amgen Inc NASDAQ/NGS:AMGN

  • Cramer's lightning round: Watch out—momentum stocks are out of favor right now
    CNBC9 days ago

    Cramer's lightning round: Watch out—momentum stocks are out of favor right now

    Jim Cramer rattles off his take on callers' favorite stocks, including a DNA sequencing play that's been dragged down by the sell-off.

  • CNBC9 days ago

    Cramer's lightning round: Watch out—momentum stocks are out of favor right now

    Jim Cramer rattles off his take on callers' favorite stocks, including a DNA sequencing play that's been dragged down by the sell-off.

  • GuruFocus.com11 days ago

    Amgen: Compelling Valuation

    Analyzing the investment prospects of this biotech company

  • Amgen’s Stock Performance and Estimates after Q3 2018
    Market Realist11 days ago

    Amgen’s Stock Performance and Estimates after Q3 2018

    Amgen (AMGN) is a biotechnology company that focuses on discovering, developing, and delivering drugs in therapeutic areas such as cardiovascular, neuroscience, and oncology. The chart below compares Amgen’s EPS and revenues since the first quarter of 2017, as well as its third-quarter estimates.

  • Ionis Pharmaceuticals’ Revenue Stream
    Market Realist11 days ago

    Ionis Pharmaceuticals’ Revenue Stream

    Ionis Pharmaceuticals’ (IONS) revenue stream is segregated into two segments: Research and Development revenues from the collaborative agreements with other companies, and Commercial Revenues. Commercial Revenues include licensing and royalty revenues and Spinraza royalties. The chart below compares the revenues for Ionis Pharmaceuticals since the first quarter of 2017.

  • Moody's11 days ago

    Moody's: Biosimilars a growing challenge biotech drugs, with European market developing more quickly than the US

    Competition from manufacturers of biosimilar drugs, or follow-on versions of complex biotech drugs, is a rising threat for branded pharmaceutical companies, Moody's Investors Service says in a new report. Branded drug makers including Roche Holding AG, Amgen Inc., AbbVie Inc. and Johnson & Johnson will see declining sales of some of their best-selling drugs over the next 12 to 18 months.

  • How Did Pharmaceutical ETFs Perform in Q3 2018?
    Market Realist12 days ago

    How Did Pharmaceutical ETFs Perform in Q3 2018?

    In this article, we’ll discuss several major ETFs in the pharmaceuticals sector and their third-quarter returns. The chart below compares the market capitalization of these pharmaceutical ETFs on October 3.

  • Amgen Gets FDA Nod for Once-Weekly Regimen of Kyprolis Combo
    Zacks12 days ago

    Amgen Gets FDA Nod for Once-Weekly Regimen of Kyprolis Combo

    Amgen (AMGN) gains an FDA approval for its sNDA with respect to a once-weekly dosing option of its multiple myeloma drug Kyprolis (70 mg/m2) combined with dexamethasone (Kd).

  • Biotech Stock Roundup: ALXN on Acquisition Spree, FDA Nod for REGN, AMGN Drugs
    Zacks12 days ago

    Biotech Stock Roundup: ALXN on Acquisition Spree, FDA Nod for REGN, AMGN Drugs

    The biotech sector grabs headlines this week with FDA approvals plus licensing and acquisition pacts.

  • At a glance: Women on the boards of California companies
    Associated Press12 days ago

    At a glance: Women on the boards of California companies

    California has become the first state to require publicly traded companies to include women on their boards of directors. The measure requires at least one female director on the board of each public corporation ...

  • 10 Stocks to Buy When the Yield Curve Inverts
    InvestorPlace13 days ago

    10 Stocks to Buy When the Yield Curve Inverts

    Will the yield curve invert, with short-term interest rates pushing their way above long-term interest rates … a relatively rare scenario that’s all too often associated with a troubled economy? It has not happened yet, but as of right now we’re as close to an inverted yield curve as we’ve been in a decade. Translation: It sure couldn’t hurt to go ahead and make plans for an inverted yield curve, just in case that’s how things take shape.